EZZ Life Science Holdings Ltd. (AU:EZZ)
ASX:EZZ
Top Page
EZZ Life Science Holdings Ltd.
(Sydney:EZZ)
Select Model
Select Model
Rating:57Neutral
Price Target:
AU$0.98
▼(-32.55% Downside)
Action:ReiteratedDate:03/18/26
The score is driven down primarily by very weak technicals (price well below key moving averages and bearish momentum). Financial fundamentals are comparatively solid (strong margins and low leverage), providing support, while valuation is mixed with an attractive dividend yield but a negative P/E.
Positive Factors
High gross and net margins
Sustained gross margins above 70% and ~10% net margin indicate durable unit economics and pricing power in nutraceuticals. This margin buffer supports reinvestment in product development, marketing, and preserves profitability during demand swings over the next several quarters.
Negative Factors
Declining and volatile revenue
Recent material revenue decline and volatility reduce visibility into growth trajectory and raise questions about market demand or distribution execution. Sustained top-line weakness can constrain scale benefits, R&D spending, and long-term expansion into Asian cross-border channels.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross and net margins
Sustained gross margins above 70% and ~10% net margin indicate durable unit economics and pricing power in nutraceuticals. This margin buffer supports reinvestment in product development, marketing, and preserves profitability during demand swings over the next several quarters.
Read all positive factors
EZZ Life Science Holdings Ltd. (EZZ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$41.87M
Dividend Yield2.81%
Average Volume (3M)49.70K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue Growth0.65%
EPS Growth-9.90%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding47,043,200
10 Day Avg. Volume67,551
30 Day Avg. Volume49,696
Financial Highlights & Ratios
PEG Ratio-2.57
Price to Book (P/B)3.85
Price to Sales (P/S)1.62
P/FCF Ratio26.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EZZ Life Science Holdings Ltd. Business Overview & Revenue Model
Company Description
EZZ Life Science Holdings Limited provides skin care and consumer health products in Australia, New Zealand, Mainland China, and internationally. The company operates in two segments, Brought in Lines and Company Owned products. It is involved in ...
How the Company Makes Money
EZZ primarily makes money by selling consumer health and nutraceutical products. Revenue is generated through product sales via (1) direct-to-consumer online channels (including cross-border e-commerce platforms) and (2) wholesale/distributor sale...
EZZ Life Science Holdings Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.40M | 66.87M | 66.44M | 37.14M | 15.02M | 22.29M |
| Gross Profit | 41.95M | 49.72M | 50.95M | 27.20M | 7.51M | 12.46M |
| EBITDA | 5.42M | 11.10M | 10.38M | 5.09M | 1.90M | 2.87M |
| Net Income | 2.89M | 6.73M | 6.96M | 3.63M | 1.31M | 2.03M |
Balance Sheet | ||||||
| Total Assets | 32.60M | 33.96M | 25.55M | 17.64M | 14.27M | 12.04M |
| Cash, Cash Equivalents and Short-Term Investments | 13.47M | 20.85M | 19.02M | 13.83M | 10.46M | 8.85M |
| Total Debt | 123.86K | 304.49K | 123.86K | 478.59K | 104.57K | 79.01K |
| Total Liabilities | 4.80M | 5.87M | 4.23M | 3.06M | 2.88M | 1.93M |
| Stockholders Equity | 27.81M | 28.09M | 21.32M | 14.58M | 11.39M | 10.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.69M | 4.09M | 5.73M | 3.91M | 1.89M | 237.42K |
| Operating Cash Flow | -2.62M | 4.35M | 6.14M | 4.01M | 1.90M | 253.53K |
| Investing Cash Flow | -862.95K | -546.93K | -441.17K | -101.78K | -13.18K | -16.12K |
| Financing Cash Flow | -2.20M | -2.17M | -582.45K | -761.72K | -277.36K | 5.44M |
EZZ Life Science Holdings Ltd. Technical Analysis
Negative
1.45
Price Trends
1.44
Negative
1.69
Negative
2.02
Negative
Market Momentum
-0.17
Negative
25.23
Positive
12.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Negative. The current price of 1.45 is above the 20-day moving average (MA) of 1.06, above the 50-day MA of 1.44, and below the 200-day MA of 2.02, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 25.23 is Positive, neither overbought nor oversold. The STOCH value of 12.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EZZ.
EZZ Life Science Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$41.87M | -25.86 | 10.35% | 2.81% | 0.65% | -9.90% | |
52 Neutral | AU$133.40M | -3.83 | -24.81% | ― | ― | 26.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | AU$80.88M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
41 Neutral | AU$51.77M | -0.70 | -134.65% | ― | ― | 55.94% | |
41 Neutral | AU$87.00M | -2.12 | -30.19% | ― | ― | 63.46% | |
41 Neutral | AU$141.70M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:EZZ
EZZ Life Science Holdings Ltd.
0.89
-0.58
-39.58%
AU:ATX
Amplia Therapeutics
0.26
0.19
271.43%
AU:IMU
Imugene
0.15
-0.98
-87.08%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:RCE
Recce Pharmaceuticals Ltd.
0.49
0.13
37.64%
AU:ALA
Arovella Therapeutics Limited
0.07
-0.02
-21.18%
EZZ Life Science Holdings Ltd. Corporate Events
EZZ Life Science Swings to Half-Year Loss as Revenue Falls but Balance Sheet Stays Solid
Feb 27, 2026
EZZ Life Science Holdings Limited reported an 18.07% decline in revenue to $24.8 million for the half-year to 31 December 2025 and swung from a prior profit to a net loss after tax of $641,298. Despite this, the group generated normalised EBITDA o...
EZZ Life Science Balances China Headwinds With Expansion, Governance Reset and Strong Cash Position
Jan 30, 2026
EZZ Life Science Holdings reported a challenging December 2025 quarter marked by softer market conditions and heightened competition in China, which drove a 26% year-on-year decline in customer receipts despite a modest improvement on the prior qu...
EZZ Life Science Appoints Gary Liu to Board with No Initial Shareholding
Jan 21, 2026
EZZ Life Science Holdings Limited has announced the appointment of Gary Liu as a director, effective 22 January 2026, and lodged an Initial Director’s Interest Notice with the ASX. The filing confirms that Liu currently holds no relevant int...
EZZ Life Science Names Gary Liu as Non-Executive Chair to Support Global Growth
Jan 21, 2026
EZZ Life Science Holdings has appointed Gary Liu as Non-Executive Chair of the board, effective immediately, bringing significant international experience in listed company leadership, capital markets, strategy and MA, with a strong focus on Asia-...
EZZ Life Science bolsters board with two new director appointments
Jan 15, 2026
EZZ Life Science Holdings Limited has strengthened its board by appointing Christine Chen as Executive Director and Janice Hsu as Non-Executive Director, effective immediately. Chen, a long-standing executive with the company and a qualified accou...
EZZ Life Science Reports Lapse of Conditional Securities
Dec 31, 2025
EZZ Life Science Holdings has notified the market of the cessation of several classes of securities, with 10,000 performance rights and a total of 130,000 ordinary fully paid shares lapsing after the conditions attached to those securities were no...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.